Skip to main content
. 2019 Nov 25;56(1):243–257. doi: 10.3892/ijo.2019.4919

Figure 6.

Figure 6

LINC00460 expression predicts a shorter PFS and OS in patients with EGFR-mutant NSCLC treated with EGFR-TKI therapy. (A) PFS following gefitinib therapy. LINC00460 expression in patients with EGFR-mutant lung adenocarcinoma was classified as low or high by using median LINC00460 expression as the cut-off. PFS after gefitinib therapy was significantly shorter for those with a high LINC00460 expression in tumors compared with those with a low LINC00460 expression in tumors (median PFS: 304 vs. 1,125 days, respectively; P=0.046). (B) OS. OS was significantly shorter for patients with a high LINC00460 expression in tumors compared with those with a low LINC00460 expression in tumors (median OS: 1,271 vs. 1,876 days, respectively; P=0.014). (C) Prediction of PFS using LINC00460 expression levels in plasma cell-free RNA. PFS was significantly shorter for patients with a high LINC00460 expression in cell-free RNA (n=15) following EGFR-TKI therapy than for those with a low LINC00460 expression (n=24) (median PFS, 549 vs. 745 days, respectively; P=0.042).